Compare JD.Com Inc (JD) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JD.Com Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? JD.Com Inc trades at $30.58 (market cap $41.80B), while Vertex Pharmaceuticals Incorporated trades at $480.35 (market cap $121.95B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 2.9× JD.Com Inc's market cap, and JD.Com Inc pays a 3.27% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.
| JD | VRTX | |
|---|---|---|
Market Cap | $41.80B | $121.95B |
Sector | Consumer Cyclical | Health |
52-Week High | $36.17 | $529.59 |
52-Week Low | $25.19 | $366.54 |
Enterprise Value | $27.96B | $116.69B |
Dividend Yield | 3.27% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JD.com trades at $30.60, up 3.31% with strong recent earnings beats. The stock shows bullish technical signals with moving averages supporting upside, while RSI levels indicate potential overbought conditions. Fundamentally, revenue grew to $1.31 trillion in 2025, though net income margin compressed to 1.05%. Analyst consensus remains strongly bullish with a $39.50 price target, representing significant upside potential from current levels.
JD offers attractive valuation with P/S of 0.22 and P/E of 21.75, but faces risks from Chinese regulatory environment and ongoing margin pressure. The company maintains robust cash flow generation and shareholder returns through buybacks. Near-term catalyst includes Q2 2026 earnings release with expected EPS of $0.86.
Vertex Pharmaceuticals (VRTX) trades at $480.51, down 1.06% on the day, with a bullish technical signal driven by moving averages. The stock shows strong profitability with a 35.51% net income margin and robust cash flow, though it faces a recent earnings miss. A major $10 billion acquisition of Crinetics Pharmaceuticals aims to expand its endocrinology portfolio, adding potential for significant future revenue growth.
The outlook remains positive with an 85.71% analyst buy rating and a $538 consensus price target, implying 12% upside. Key risks include integration challenges from the acquisition and reliance on cystic fibrosis treatments. Earnings growth and successful pipeline execution are critical catalysts for sustained appreciation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About JD.Com Inc
JD.com is China's second-largest e-commerce company after Alibaba in terms of gross merchandise volume, offering a wide selection of authentic products at competitive prices, with speedy and reliable delivery. The company has built its own nationwide fulfilment infrastructure and last-mile delivery network, staffed by its own employees, which supports both its online direct sales, its online marketplace and omnichannel businesses.
Read more on JD →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
